PNET-PRISM: a multicenter-validated radiomics nomogram for noninvasive grading of pancreatic neuroendocrine tumors.
Authors
Affiliations (5)
Affiliations (5)
- Department of Radiology, Changhai Hospital, Shanghai, China.
- Department of Radiation Oncology, Changhai Hospital, Shanghai, China.
- Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
- Department of Radiology, Changhai Hospital, Shanghai, China. [email protected].
- Department of Radiology, Changhai Hospital, Shanghai, China. [email protected].
Abstract
Accurate preoperative grading of pancreatic neuroendocrine tumors (PNETs) is essential for optimal treatment selection, yet endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) yields inadequate tissue in up to 40% of cases and carries procedural risks, necessitating reliable noninvasive alternatives. This multicenter retrospective study included 407 surgically confirmed PNET patients across training (n = 244), validation (n = 106), and external test (n = 57) cohorts. We developed a pancreatic radiomics integrated scoring model for PNET (PNET-PRISM), integrating multidimensional CT radiomics features from intratumoral, peritumoral, habitat, and deep learning domains using automated segmentation. A multidimensional deep learning radiomics score (M-DLR Score) was constructed from 13,542 features and combined with clinical variables for preoperative grade prediction. PNET-PRISM demonstrated robust performance with AUCs of 0.92, 0.89, and 0.87 in training, validation, and external test sets, respectively, significantly outperforming clinical-only models (ΔAUC = 0.15-0.22, all p < 0.001). The model achieved perfect sensitivity (100%) in external validation and provided accurate grading in 13 of 25 patients (52%) where EUS-FNA yielded insufficient tissue. Net Reclassification Improvement analysis demonstrated significant improvement over clinical models across all datasets (NRI = 0.318-0.406, p ≤ 0.070). M-DLR Score stratification showed a significant association with progression-free survival (HR = 2.050, 95% CI: 1.484-2.833, p < 0.001). This validated radiomics-based nomogram serves as a powerful noninvasive decision-support tool for PNET risk stratification, effectively complementing EUS-FNA limitations and enabling optimized treatment pathways, particularly when biopsy is contraindicated or nondiagnostic. This CT-based radiomics nomogram reliably grades pancreatic neuroendocrine tumors (PNETs) and predicts prognosis. This study addresses endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) limitations and advances clinical radiology by enabling safer triage and personalized management when tissue diagnosis is uncertain or unavailable. A CT-based pancreatic radiomics integrated scoring model for PNET (PNET-PRISM) helps when endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) fails. In 407 patients, PRISMPNET-PRISM achieved a high area under the curve (AUC) and 100% external sensitivity for triage. The multidimensional deep learning radiomics (M-DLR) score stratified progression-free survival (hazard ratio (HR) ≈ 2.05) and rescued nondiagnostic biopsies.